Author:
Gerullis Holger,Bergmann Lothar,Maute Luise,Eimer Christoph,Otto Thomas
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference22 articles.
1. Patard JJ, Pouessel D, Bensalah K, Culine S (2008) Targeted therapy in renal cell carcinoma. World J Urol 26(2):135–140
2. Trigo J, Bellmunt J (2008) Current strategies in the treatment of renal-cell cancer: targeted therapies. Med Clin 130(10):380–392
3. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA (2003) Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641–4652
4. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, Interferon Alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
5. Bhojani N, Jeldres C, Patard J, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz P (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917–930
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献